$-0.02
(Market cap
$92 Mln
Revenue (TTM)
$68 Mln
P/E Ratio
1
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
1.2 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$2.9
-
Face value
--
-
Shares outstanding
33,350,993
10 Years Aggregate
CFO
$-869.61 Mln
EBITDA
$-1,056.90 Mln
Net Profit
$-869.10 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fortress Biotech (FBIO)
| -26.0 | -13.4 | 2.3 | -9.1 | -23.3 | -12.2 | -4.1 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Fortress Biotech (FBIO)
| 80.7 | -32.5 | -69.6 | -73.6 | -21.1 | 23.3 | 198.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fortress Biotech (FBIO)
|
2.7 | 92.4 | 68.5 | 111.8 | 226.1 | 78 | 1 | 0.6 |
| 17.9 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 208.4 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 75.4 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 112.8 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.4 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 289.7 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.6 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 128.7 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Fortress Biotech (FBIO)
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea;... Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Read more
-
Executive Chairman, President & CEO
Dr. Lindsay Allan Rosenwald
-
Executive Chairman, President & CEO
Dr. Lindsay Allan Rosenwald
-
Headquarters
Bay Harbor Islands, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Fortress Biotech (FBIO)
What is the current share price of Fortress Biotech Inc (FBIO) Today?
The share price of Fortress Biotech Inc (FBIO) is $2.71 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Fortress Biotech Inc (FBIO) has given a return of -23.27% in the last 3 years.
What is the current PB & PE ratio of Fortress Biotech Inc (FBIO)?
The P/E ratio of Fortress Biotech Inc (FBIO) is 1.00 times as on 28-Aug-2026, a 97 discount to its peers’ median range of 37.32 times.
The P/B ratio of Fortress Biotech Inc (FBIO) is 0.57 times as on 28-Aug-2026, a 93 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
19.20 |
2.62 |
2024 |
-0.89 |
1.80 |
2023 |
-0.39 |
1.04 |
2022 |
-0.05 |
0.10 |
2021 |
-0.02 |
0.01 |
What is the 52 Week High and Low of Fortress Biotech Inc (FBIO)?
The 52-week high and low of Fortress Biotech Inc (FBIO) are Rs 4.53 and Rs 2.18 as of 04-Sep-2026.
What is the market cap of Fortress Biotech Inc (FBIO)?
Fortress Biotech Inc (FBIO) has a market capitalisation of $ 92 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Fortress Biotech Inc (FBIO)?
Before investing in Fortress Biotech Inc (FBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.